NVCR – novocure limited - ordinary shares (US:NASDAQ)

DELAYED
$ usd
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
1D
5D
1M
3M
YTD
1Y
3Y
1 Day NVCR SPY QQQ SPX
Date
Time
Symbol
Company Name
Action
%Chg
2/26/2026
07:00 am
nvcr
novocure limited - ordinary shares
BEAT
-7.0%
10/30/2025
07:00 am
nvcr
novocure limited - ordinary shares
BEAT
-7.1%
7/24/2025
07:00 am
nvcr
novocure limited - ordinary shares
BEAT
-24.0%
4/24/2025
07:00 am
nvcr
novocure limited - ordinary shares
BEAT
-2.3%
Earnings are essential to understanding the financial health of a company listed on any Stock Exchange. But what are Earnings, how are they calculated, when are they announced, and how are they used to make sound investment decisions?
The answers are right here.
Stock Stats
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Order Stats
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
Top News Gainers
1/16 Novocure Ltd (NASDAQ: NVCR) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 11.0%
7/25 Q2/2019 6/30/2019 EPS -0.010 ZacksConsensus -0.070 ActVsEst 0.060 - Beat 8.6%
3/19 Novocure Announces Optune Lua™ as the Brand Name for the NovoTTF-100L™ System 8.2%
3/4 Novocure Ltd (NASDAQ: NVCR) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 7.8%
4/7 Novocure Ltd (NASDAQ: NVCR) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a price target on the stock. 7.7%
5/23 FDA Approves the NovoTTF-100LTM System in Combination with Chemotherapy for the Treatment of Malignant Pleural Mesothelioma 7.3%
6/27 Novocure Ltd (NASDAQ: NVCR) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. 7.1%
8/14 Form 4 NovoCure Ltd For: Aug 12 Filed by: LEUNG GABRIEL 5.2%
10/31 NovoCure Limited (NVCR) CEO Asaf Danziger on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] 5.2%
1/7 Novocure Ltd (NASDAQ: NVCR) had its "buy" rating re-affirmed by analysts at Mizuho. They now have a $91.00 price target on the stock. 5.2%
Top News Decliners
4/30 Q1/2020 3/31/2020 EPS 0.040 ZacksConsensus 0.050 ActVsEst (0.010) - Miss -12.1%
3/20 German Federal Joint Committee Updates Medical Care Directive to include Tumor Treating Fields, establishing National Reimbursement for Optune in Germany -10.5%
4/7 Novocure Ltd (NASDAQ: NVCR) had its price target lowered by analysts at Wells Fargo & Co from $90.00 to $82.00. They now have an "overweight" rating on the stock. -9.6%
5/1 Novocure Ltd (NASDAQ: NVCR) had its "hold" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $78.00 price target on the stock. -8.4%
9/9 Novocure Announces 27 Presentations at the American Society for Radiation Oncology 2019 Annual Meeting -8.3%
3/10 Form 4 NovoCure Ltd For: Mar 06 Filed by: GROENHUYSEN WILHELMUS CM -8.1%
1/2 Novocure Ltd (NASDAQ: NVCR) was downgraded by analysts at Evercore ISI to an "outperform" rating. -7.9%
3/2 Form 4 NovoCure Ltd For: Feb 27 Filed by: Shah Pritesh -7.4%
10/25 Novocure Ltd (NASDAQ: NVCR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $79.00 price target on the stock. -6.6%
1/13 Form 8-K NovoCure Ltd For: Jan 10 -5.6%

Don’t Miss Out On The Next BIG Stock Move

Thanks for submitting the form.
NVCR – novocure limited - ordinary shares (US:NASDAQ)
DELAYED
$ usd
1D
5D
1M
3M
YTD
1Y
3Y
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
NVCR
SPY
QQQ
SPX
NVCR – novocure limited - ordinary shares (US:NASDAQ)
DELAYED
$ usd
1D
5D
1M
3M
YTD
1Y
3Y
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
NVCR SPY QQQ SPX
Stock Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
Stock Stats
Order Stats
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
News
3/26
07:00 am
nvcr
Low
Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer
3/2
07:00 am
nvcr
Low
Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer
2/27
10:34 pm
nvcr
Low
NovoCure Limited Q4 2025 Earnings Call Summary [Yahoo! Finance]
2/27
04:30 pm
nvcr
Low
Novocure to Participate in 2026 Leerink Global Healthcare Conference
2/26
01:58 pm
nvcr
Medium
NovoCure (NVCR) had its price target raised by HC Wainwright from $47.00 to $49.00. They now have a "buy" rating on the stock.
2/26
07:51 am
nvcr
Low
NovoCure: Q4 Earnings Snapshot [Yahoo! Finance]
2/26
07:10 am
nvcr
Medium
NovoCure GAAP EPS of -$0.22 beats by $0.19, revenue of $174.35M beats by $0.99M [Seeking Alpha]
2/26
07:00 am
nvcr
Medium
Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update
2/24
07:00 am
nvcr
Medium
Tumor Treating Fields (TTFields) Therapy to be Covered for Patients with Newly Diagnosed Glioblastoma Through British Columbia Cancer (BC Cancer)
2/26/2026
07:00 am
nvcr
-7.0%
BEAT
10/30/2025
07:00 am
nvcr
-7.1%
BEAT
7/24/2025
07:00 am
nvcr
-24.0%
BEAT
4/24/2025
07:00 am
nvcr
-2.3%
BEAT
Earnings are essential to understanding the financial health of a company listed on any Stock Exchange. But what are Earnings, how are they calculated, when are they announced, and how are they used to make sound investment decisions? The answers are right here.
2/12
07:17 am
Reiterates
Buy
Buy
HC Wainwright
Medium
-4.3%
1/15
09:19 am
Reiterates
Neutral
Neutral
Wedbush
Low
0.5%
1/15
09:19 am
Reiterates
Neutral
Neutral
Wedbush
Low
0.5%
1/15
09:02 am
Reiterates
Neutral
Neutral
Wedbush
Low
1.6%
1/15
09:02 am
Reiterates
Neutral
Neutral
Wedbush
Low
1.6%
3/26
11:52 am
nvcr
Low
Form SCHEDULE 13G/A NovoCure Ltd Filed by: VANGUARD GROUP INC
3/26
07:01 am
nvcr
Low
Form 8-K NovoCure Ltd For: Mar 26
3/5
04:34 pm
nvcr
Medium
Form 4 NovoCure Ltd For: Mar 04 Filed by: Leupin Nicolas
3/5
04:33 pm
nvcr
Medium
Form 4 NovoCure Ltd For: Mar 03 Filed by: Ben Arye Barak
3/5
04:33 pm
nvcr
Medium
Form 4 NovoCure Ltd For: Mar 04 Filed by: Cordova Ashley
3/5
04:32 pm
nvcr
Medium
Form 4 NovoCure Ltd For: Mar 03 Filed by: Weinberg Uri
3/5
04:32 pm
nvcr
Medium
Form 4 NovoCure Ltd For: Mar 03 Filed by: Brackmann Christoph
3/5
04:31 pm
nvcr
Medium
Form 4 NovoCure Ltd For: Mar 03 Filed by: Puri Michal Nath
3/5
04:31 pm
nvcr
Medium
Form 4 NovoCure Ltd For: Mar 03 Filed by: Paravasthu Mukund
Show more
Top News Gainers
1/16 Novocure Ltd (NASDAQ: NVCR) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 11.0%
7/25 Q2/2019 6/30/2019 EPS -0.010 ZacksConsensus -0.070 ActVsEst 0.060 - Beat 8.6%
3/19 Novocure Announces Optune Lua™ as the Brand Name for the NovoTTF-100L™ System 8.2%
3/4 Novocure Ltd (NASDAQ: NVCR) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 7.8%
4/7 Novocure Ltd (NASDAQ: NVCR) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a price target on the stock. 7.7%
5/23 FDA Approves the NovoTTF-100LTM System in Combination with Chemotherapy for the Treatment of Malignant Pleural Mesothelioma 7.3%
6/27 Novocure Ltd (NASDAQ: NVCR) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. 7.1%
8/14 Form 4 NovoCure Ltd For: Aug 12 Filed by: LEUNG GABRIEL 5.2%
10/31 NovoCure Limited (NVCR) CEO Asaf Danziger on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] 5.2%
1/7 Novocure Ltd (NASDAQ: NVCR) had its "buy" rating re-affirmed by analysts at Mizuho. They now have a $91.00 price target on the stock. 5.2%
Top News Decliners
4/30 Q1/2020 3/31/2020 EPS 0.040 ZacksConsensus 0.050 ActVsEst (0.010) - Miss -12.1%
3/20 German Federal Joint Committee Updates Medical Care Directive to include Tumor Treating Fields, establishing National Reimbursement for Optune in Germany -10.5%
4/7 Novocure Ltd (NASDAQ: NVCR) had its price target lowered by analysts at Wells Fargo & Co from $90.00 to $82.00. They now have an "overweight" rating on the stock. -9.6%
5/1 Novocure Ltd (NASDAQ: NVCR) had its "hold" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $78.00 price target on the stock. -8.4%
9/9 Novocure Announces 27 Presentations at the American Society for Radiation Oncology 2019 Annual Meeting -8.3%
3/10 Form 4 NovoCure Ltd For: Mar 06 Filed by: GROENHUYSEN WILHELMUS CM -8.1%
1/2 Novocure Ltd (NASDAQ: NVCR) was downgraded by analysts at Evercore ISI to an "outperform" rating. -7.9%
3/2 Form 4 NovoCure Ltd For: Feb 27 Filed by: Shah Pritesh -7.4%
10/25 Novocure Ltd (NASDAQ: NVCR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $79.00 price target on the stock. -6.6%
1/13 Form 8-K NovoCure Ltd For: Jan 10 -5.6%